Franco Scalambra

Synthesis and Antiproliferative Activity of [RuCp(PPh3)2(HdmoPTA)](OSO2CF3)2 (HdmoPTA = 3,7-H-3,7-Dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)

The complex [RuCp(PPh3)2(HdmoPTA)](OSO2CF3)2 (2; HdmoPTA = 3,7-H-3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane) was synthesized and characterized. Its crystal structure was determined by single-crystal X-ray diffraction. The complex showed a more potent antiproliferative activity than cisplatin against a representative panel of human cancer cells.

First water-soluble backbone Ru-Ru-Ni heterometallic organometallic polymer.

The water-soluble backbone heterometallic polymer {[(PTA)2 CpRu-μ-CN-RuCp(PTA)2 -μ-NiCl3 ]}n (2) is synthesized using a reproducible and robust method and fully characterized by X-ray single crystal diffraction. The Ru-Ru-Ni polymer is found to be stable in the solid state and soluble in water. Nuclear magnetic resonance (NMR) and light scattering studies show that the polymer is stable in water for several days in air.

Ruthenium complexes containing mPTA and thiopurines bis(8-thiotheophylline)-(CH2)n (n = 1 – 3; mPTA = N-methyl-1,3,5-triaza-7-phosphaadamantane)

Abstract Thiopurines bis(S-8-thiotheophylline)methane (MBTTH2), 1,2-bis(S-8-thiotheophylline)ethane (EBTTH2), and 1,3-bis(S-8-thiotheophylline)propane (PBTTH2) were reacted with [RuClCp(mPTA)2](CF3SO3)2 in water to afford the bis-ruthenium complexes [{RuCp(mPTA)2}2-μ-(L-κN7,N′7)](CF3SO3)4 (1: L = MBTT; 2: L = EBTT; 3: L = PBTT), which have been characterized by elemental analysis, IR, and multinuclear NMR (1H, 13C{1H}, 31P{1H} and 19F{1H}) spectroscopy). Diffusion experiments for 1 were carried out. Proposed structures for the three complexes were also supported by theoretical calculations. Cyclic voltammetry showed that these complexes are characterized by two one-electron irreversible oxidative response (RuII – RuII/RuIII – RuII; RuIII – RuII/RuIII – RuIII). Complexes showed poor antiproliferative activity against cisplatin-sensitive T2 human cell line and the cisplatin-resistant SKOV3 cell line.